gen-001
Cell therapyexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04601402)
Timeline
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05998447 | Phase 2 | Sep 18, 2023 | Genome & Company, Merck |
| NCT05419362 | Phase 2 | Apr 7, 2022 | Genome & Company, Merck KGaA, Pfizer, Sungkyunkwan University |
| NCT05079503 | N/A | Dec 15, 2021 | Korea University, Seoul National University |
| NCT04601402 | Phase 1 | Oct 31, 2020 | Genome & Company, Merck KGaA, Oregon Health and Science University, Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genome & Company | Academic/Hospital | 3 | 3 | 2 | 2020 |
| Merck KGaA | For profit | 2 | 0 | 2 | 2020 |
| Pfizer | For profit | 2 | 0 | 2 | 2020 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1